Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine is a research paper published in The Journal of Allergy and Clinical Immunology In Practice (2020). On theSindex it has a DataRank of 0. It has been cited 37 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Teva Pharmaceutical Industries
AstraZeneca
Regeneron Pharmaceuticals
Sanofi
Boston Scientific Corporation
Johnson and Johnson
Merck Sharp and Dohme
Aeglea BioTherapeutics
F. Hoffmann-La Roche
GlaxoSmithKline
U.S. Department of Veterans Affairs
National Institutes of Health
Novartis
U.S. Department of Defense
Genentech
American Lung Association
Boehringer Ingelheim
Chiesi Farmaceutici
Merck
Roche
FWCI
2.15
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals